THERAPY DOSSIER · th-5c794ed9b5f3

Stromal cell-derived factor-1 (SDF-1/CXCL12), given exogenously or stabilised endogenously; compared and combined with thrombopoietin

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01082094 ↗PHASE1completed

An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure

Heart Failure

Enrolment: 17 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24735964 ↗2014Reported benefit

SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury.

MouseRadiationC57BL/6FemaleIntravenous administration of SDF-1, or stabilisation of endogenous SDF-1

Model: Radiation injury causing thrombocytopenia

Intravenous SDF-1 and stabilisation of endogenous SDF-1 acutely increased megakaryocyte-vasculature association and thrombopoiesis without changing megakaryocyte number, and manipulation of SDF-1 gradients improved radiation-induced thrombocytopenia additively with earlier thrombopoietin treatment.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…